Monitor warrant exercise activity, as the potential $30 million in proceeds could improve the company's financial position. The resale of shares by selling stockholders may increase trading volume and potentially impact stock price volatility.
Price Chart
Executive Summary
PAVmed Inc. has filed an S-3 shelf registration to register 9,230,786 shares of common stock for resale by selling stockholders. These shares originated from a February 2026 private placement of Series D convertible preferred stock and warrants, which were converted into common stock in March 2026. The company will not receive proceeds from the resale of these shares but could receive up to $30 million if the warrants are exercised. This registration facilitates future liquidity for investors but does not raise new capital for the company.
Key Financial Metrics
Key Facts
- PAVmed filed an S-3 shelf registration to register 9,230,786 shares of common stock for resale by selling stockholders.
- The shares originated from the conversion of 30,000 shares of Series D convertible preferred stock into 4,615,393 common shares, plus 4,615,393 shares issuable upon warrant exercise.
- The company will not receive proceeds from the resale of these registered shares.
- The company may receive up to $30 million if the outstanding warrants are exercised.
- The registration supports investor liquidity but does not represent a new capital raise for the company.
Financial Impact
The company could receive up to $30,000,000 if all warrants are exercised. The resale of 9,230,786 shares by selling stockholders will not provide proceeds to the company.
Risk Factors
- Potential dilution if warrants are exercised
- Increased stock price volatility from selling stockholder activity
- No proceeds to company from resale of registered shares
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-018158 |
| Exhibit: ex10-1.htm | 0001493152-26-018158 |
| Exhibit: ex107.htm | 0001493152-26-018158 |
| Exhibit: ex5-1.htm | 0001493152-26-018158 |
| Exhibit: ex23-2.htm | 0001493152-26-018158 |
| Exhibit: ex23-1.htm | 0001493152-26-018158 |
| Document: 0001493152-26-018158-index-headers.html | 0001493152-26-018158 |
| Document: 0001493152-26-018158-index.html | 0001493152-26-018158 |
| Document: 0001493152-26-018158.txt | 0001493152-26-018158 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC 13G/A | $2.17 | awaiting T+60 | — | $2.26 (+4.15%) |
Oct 22, 2026 4d ago | 8-K | $2.17 | awaiting T+60 | — | $2.26 (+4.15%) |
May 15, 2026 23w ago | 8-K | $6.53 $4.71 | ▲ +27.87% | ▲ +32.39% | $2.26 (+65.39%) |
Apr 20, 2026 27w ago | S-3 | $9.15 $6.02 | ▼ −34.17% | ▼ −41.07% | $2.26 (−75.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers